AU2017323504A1 - Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same - Google Patents

Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same Download PDF

Info

Publication number
AU2017323504A1
AU2017323504A1 AU2017323504A AU2017323504A AU2017323504A1 AU 2017323504 A1 AU2017323504 A1 AU 2017323504A1 AU 2017323504 A AU2017323504 A AU 2017323504A AU 2017323504 A AU2017323504 A AU 2017323504A AU 2017323504 A1 AU2017323504 A1 AU 2017323504A1
Authority
AU
Australia
Prior art keywords
composition
crystals
liquid
oltipraz
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017323504A
Other languages
English (en)
Other versions
AU2017323504A8 (en
Inventor
Bret Berner
Corey Jay BLOOM
Barbara-Jean Anne BORMANN-KENNEDY
Bomi FRAMROZE
Anthony Chris GARLAND
Michael Edward Grass
Casey Keith JAGER
Mark Joseph Kastantin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST IP Holding AG
Original Assignee
ST IP Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST IP Holding AG filed Critical ST IP Holding AG
Priority claimed from PCT/IB2017/001312 external-priority patent/WO2018047013A1/en
Publication of AU2017323504A1 publication Critical patent/AU2017323504A1/en
Publication of AU2017323504A8 publication Critical patent/AU2017323504A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017323504A 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same Abandoned AU2017323504A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201611031045 2016-09-12
IN201611031045 2016-09-12
US201662412681P 2016-10-25 2016-10-25
US62/412,681 2016-10-25
PCT/IB2017/001312 WO2018047013A1 (en) 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same

Publications (2)

Publication Number Publication Date
AU2017323504A1 true AU2017323504A1 (en) 2019-05-02
AU2017323504A8 AU2017323504A8 (en) 2019-06-06

Family

ID=60569947

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017323504A Abandoned AU2017323504A1 (en) 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same

Country Status (6)

Country Link
US (1) US11426403B2 (cg-RX-API-DMAC10.html)
EP (1) EP3509642A1 (cg-RX-API-DMAC10.html)
JP (1) JP2019531344A (cg-RX-API-DMAC10.html)
KR (1) KR102658015B1 (cg-RX-API-DMAC10.html)
CN (1) CN109996562A (cg-RX-API-DMAC10.html)
AU (1) AU2017323504A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
AU2017322544B2 (en) * 2016-09-12 2022-06-02 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
CA2408152A1 (en) 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US7012148B2 (en) 2001-09-25 2006-03-14 Trustees Of Dartmouth College Compositions and methods for thionation during chemical synthesis reactions
US7199122B2 (en) 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
JP2005522446A (ja) 2002-02-13 2005-07-28 ソルベイ・フアルマ 肺癌の化学予防におけるアネトールジチオールチオンの使用
KR100491318B1 (ko) 2002-11-26 2005-05-24 씨제이 주식회사 올티프라즈(Oltipraz) 제조방법
ATE357932T1 (de) 2003-12-22 2007-04-15 Alcon Inc Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
KR100629771B1 (ko) 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
FR2879444B1 (fr) 2004-12-22 2007-05-18 Oreal Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie
US20070036733A1 (en) 2005-08-12 2007-02-15 Takasago International Corp. (Usa) Sensation masking composition
CN101257949B (zh) 2005-08-15 2011-01-19 奇华顿股份有限公司 清凉化合物
US7803353B2 (en) 2006-03-29 2010-09-28 The Procter & Gamble Company Oral care compositions having improved consumer aesthetics and taste
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
ATE540667T1 (de) 2007-06-13 2012-01-15 Givaudan Sa Verbindungen mit kühlender wirkung
US20110003747A1 (en) 2007-07-20 2011-01-06 Coloumbe Pierre A Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
WO2009099830A2 (en) 2008-01-31 2009-08-13 Mcneil-Ppc, Inc. Edible film-strips for immediate release of active ingredients
US8142806B2 (en) 2008-03-10 2012-03-27 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
US8858995B2 (en) 2008-03-10 2014-10-14 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
KR101057485B1 (ko) 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
WO2010128026A2 (en) 2009-05-05 2010-11-11 Givaudan Sa Organic compounds
CN102451469A (zh) * 2010-10-26 2012-05-16 沈阳药科大学 一类用于难溶性药物纳米系统的高效稳定剂
CA2835293C (en) 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
EP2757887B1 (en) 2011-09-22 2017-04-26 VIIV Healthcare UK Limited Pyrrolopyridinone compounds and methods for treating hiv
US10500282B2 (en) * 2012-12-19 2019-12-10 Kashiv Biosciences, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
WO2015023889A1 (en) 2013-08-16 2015-02-19 Luminus Biosciences Inc. Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease
EP3110510A1 (en) 2014-02-27 2017-01-04 The Procter & Gamble Company Oral care compositions with a reduced bitter taste perception
US20160376259A1 (en) * 2015-06-25 2016-12-29 St Ip Holding Ag Methods for Preparing Oltipraz
WO2016207914A2 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for preparing oltipraz
ITUB20159655A1 (it) 2015-12-23 2017-06-23 Bormioli Rocco Spa Capsula di sicurezza di un contenitore.
ITUA20162141A1 (it) 2016-03-31 2017-10-01 Bormioli Pharma Spa Capsula di chiusura
AU2017322544B2 (en) * 2016-09-12 2022-06-02 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
KR20180123796A (ko) 2017-05-10 2018-11-20 서울대학교산학협력단 Nrf2-NEMO 경로 활성화를 통한 과중력으로 인한 세포괴사의 억제용 조성물 및 방법

Also Published As

Publication number Publication date
EP3509642A1 (en) 2019-07-17
US20190209556A1 (en) 2019-07-11
AU2017323504A8 (en) 2019-06-06
US11426403B2 (en) 2022-08-30
CN109996562A (zh) 2019-07-09
JP2019531344A (ja) 2019-10-31
KR102658015B1 (ko) 2024-05-21
KR20190089852A (ko) 2019-07-31

Similar Documents

Publication Publication Date Title
WO2018047013A1 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
US20210052580A1 (en) Combination Compositions and Therapies Comprising 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, and Methods of Making and Using Same
US11931321B2 (en) Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same
DK2600850T3 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NOCICEPTIVE PAIN
RU2589830C2 (ru) ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ- ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b]ИНДОЛ]-4-АМИН
WO2018047002A1 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
JP2023113634A (ja) 4-メチル-5-(ピラジン-2-イル)-3h-1,2-ジチオール-3-チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法
US11426403B2 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same
US9326977B2 (en) Anti-inflammatory compounds
CN121568678A (zh) 局部抗氧化剂组合物及其使用方法
CN105434409A (zh) 组合物、组合物的用途及制造方法
US11135220B1 (en) Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
JP4590224B2 (ja) トラニラストまたは薬理学的に許容される塩を含有する懸濁性医薬組成物
CN118593450A (zh) 氨磷汀复合脂质纳米粒的制备方法及其应用
HK40073161B (en) Compositions and methods for treating central nervous system disorders
HK1183611A (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
HK1183611B (en) Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 33 , NO 16 , PAGE(S) 2369 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ST IP HOLDING AG, APPLICATION NO. 2017323504, UNDER INID (72) CORRECT THE CO-INVENTOR TO BERNER, BRET

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted